Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche; Artur Bauhofer; Miguel Ãngel Gomez Bravo; Georges Philippe Pageaux; Fabien Zoulim; Alejandra Otero; Martin Prieto; Carmen Baliellas; Didier Samuel

doi:10.12659/AOT.936162

10 May 2022 : Original article

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche^1BCDE, Artur Bauhofer^2ACDEF*, Miguel Ãngel Gomez Bravo^3BCDE, Georges Philippe Pageaux^4ABCDE, Fabien Zoulim^5BDE, Alejandra Otero^6BC, Martin Prieto^78BC, Carmen Baliellas^9BC, Didier Samuel^1ACDE

DOI: 10.12659/AOT.936162

Ann Transplant 2022; 27:e936162

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Median scores of the 4 TSQM-11 dimensions at the baseline and 2-year FU visits. Score range: 0 (extremely dissatisfied) to 100 (extremely satisfied). * P<0.05 for change vs baseline visit at the 2-year FU (Prepared with Microsoft Office 2016).

Back to the Article

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Your Privacy